Theories behind Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer and update on current management  

作　　者：Hanna Maroof Louise Paramore Ahmed Ali 

机构地区：[1]Department of Urology,Frimley Park Hospital,Portsmouth Rd,Frimley,Camberley GU167UJ,United Kingdom

出　　处：《Cancer Pathogenesis and Therapy》2024年第2期74-80,共7页癌症发生与治疗（英文）

摘　　要：Bladder cancer encapsulates a wide spectrum of disease severities,with non-muscle invasive bladder cancer(NMIBC)representing an entirely different entity from muscle-invasive disease.Bacillus Calmette-Guerin(BCG)is one of the most successful intravesical treatment methods for patients diagnosed.However,a considerable pro-portion of patients fail to respond to BCG treatment.Given the propensity for recurrence in patients with high-risk bladder cancer,these patients present with surgical dilemmas.There is currently no gold standard for salvage treatment post-BCG failure or unified definition as to what that means.In this review,we discuss the mechanisms of action and pathophysiology of BCG,potential theories behind BCG failure,and the scope of novel treatments forthis surgical conundrum.

关 键 词：CYSTECTOMY HYPERTHERMIA Induced IMMUNOTHERAPY Mycobacterium bovis Non-muscle-invasive bladder cancer 

分 类 号：R737.14[医药卫生—肿瘤]